Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O’Dwyer, Michael, Perrot, Aurore, Venner, Christopher P., Weisel, Katja, Mace, Joseph R., Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Qi, Ming, Usmani, Saad Z.·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1817249

Cited by (1,013)

Items 1,001–1,013 of 1,013

  1. Additional file 1 of Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States
    Medhekar, Rohan, Ran, Tao, Fu, Alex Z. · 2022 · Figshare
  2. Additional file 1 of Measurable residual disease in multiple myeloma: ready for clinical practice?
    Burgos, Leire, Puig, Noemi, Cedena, Maria-Teresa · 2020 · Figshare
  3. Additional file 3 of Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coach
    Paul A. F. Geerts, Job F. H. Eijsink, Albine Moser, ter Horst, Peter, Boersma, Cornelis, Postma, Maarten · 2023 · Figshare
  4. Additional file 2 of Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer
    Chen, Sheng, Li, Xiangrong, Wen Ao · 2024 · Figshare
  5. Additional file 1 of Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019
    Balmaceda, Nicole, Aziz, Muhammad, Chandrasekar, Viveksandeep Thoguluva, Brian Lee McClune, Suman Kambhampati, Leyla Osman Shune, Abdallah, Al-Ola, Faiz Anwer, Aneela Majeed, Muzaffar H. Qazilbash et al. · 2021 · Figshare
  6. Additional file 1 of Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials
    Ye, Wu, Wu, Xia, Liu, Xiaoyan, Xue Li Zheng, Deng, Jili, Gong, Yuping · 2021 · Figshare
  7. Additional file 2 of Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coach
    Paul A. F. Geerts, Job F. H. Eijsink, Albine Moser, ter Horst, Peter, Boersma, Cornelis, Postma, Maarten · 2023 · Figshare
  8. Additional file 1 of Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
    Shebli Atrash, Philippe Thompson‐Leduc, TAI, Ming-Hui, Shuchita Kaila, Kathleen S Gray, Isabelle Ghelerter, LAFEUILLE, Marie-Hélène, Patrick Lefèbvre, ROSSI, Adriana · 2021 · Figshare
  9. Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma
    Kenshi Suzuki, Hiroshi Kosugi, Toshiro Ito et al. · 2026 · Japanese Journal of Clinical Oncology
  10. Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS
    Saad Z. Usmani, Thierry T.F. Facon, Vânia Hungria, Nizar Jacques Bahlis, Christopher Paul Venner, Marc Justin Braunstein, Luděk Pour, Josep Maria Martí, Supratik Basu, Yael Chava Cohen et al. · 2026 · Journal of Clinical Oncology
  11. Monoclonal Antibodies and Antibody-Drug Conjugates
    Ioannis Ntanasis‐Stathopoulos, Evangelos Terpos, Meletios Athanasios Dimopoulos · 2026 · The Cancer Journal
  12. Tailoring Therapy for Frail and Elderly Myeloma Patients
    Thomas George, Raphael Elie Szalat · 2026 · The Cancer Journal
  13. Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial
    Haiyan He, Jingjing Shang, Yafei Wang et al. · 2026 · The Lancet Haematology